Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXS NASDAQ:ALGS NASDAQ:DARE NASDAQ:NCNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/AALGSAligos Therapeutics$4.91-8.1%$6.53$4.80▼$13.69$33.04M2.25138,153 shs127,991 shsDAREDare Bioscience$1.88-13.8%$2.23$1.27▼$9.19$32.65M1.07437,456 shs450,663 shsNCNANuCana$1.95-3.5%$2.00$1.33▼$40.00$8.41M2.1843,355 shs44,698 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+1,712.46%ALGSAligos Therapeutics+3.89%-7.77%-15.91%-23.50%-15.10%DAREDare Bioscience+5.83%-4.39%-33.33%+42.48%-29.68%NCNANuCana-0.49%-11.01%-7.76%-6.48%-78.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/AALGSAligos Therapeutics$4.91-8.1%$6.53$4.80▼$13.69$33.04M2.25138,153 shs127,991 shsDAREDare Bioscience$1.88-13.8%$2.23$1.27▼$9.19$32.65M1.07437,456 shs450,663 shsNCNANuCana$1.95-3.5%$2.00$1.33▼$40.00$8.41M2.1843,355 shs44,698 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+1,712.46%ALGSAligos Therapeutics+3.89%-7.77%-15.91%-23.50%-15.10%DAREDare Bioscience+5.83%-4.39%-33.33%+42.48%-29.68%NCNANuCana-0.49%-11.01%-7.76%-6.48%-78.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/AALGSAligos Therapeutics 2.86Moderate Buy$38.50684.11% UpsideDAREDare Bioscience 2.33Hold$10.00431.91% UpsideNCNANuCana 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest NCNA, ADXS, DARE, and ALGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/28/2026ALGSAligos Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.005/21/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/21/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.004/21/2026NCNANuCana Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026ALGSAligos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DAREDare Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/26/2026ALGSAligos Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/26/2026ALGSAligos Therapeutics Westpark CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.003/19/2026ALGSAligos Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.003/18/2026ALGSAligos Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M11.05N/AN/A($2.06) per share-0.29ALGSAligos Therapeutics$2.19M13.88N/AN/A$8.67 per share0.57DAREDare Bioscience$1.03M27.34N/AN/A$0.20 per share9.40NCNANuCanaN/AN/AN/AN/A$7.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$5.02N/AN/AN/AN/AN/AN/AN/AALGSAligos Therapeutics-$24.19M-$8.69N/AN/AN/A-1,919.68%-139.47%-90.88%8/5/2026 (Estimated)DAREDare Bioscience-$13.40M-$0.95N/AN/AN/AN/AN/A-46.22%8/13/2026 (Estimated)NCNANuCana-$38.71M-$2.98N/AN/AN/AN/A-153.61%-116.03%8/13/2026 (Estimated)Latest NCNA, ADXS, DARE, and ALGS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026NCNANuCana-$2.6440-$1.25+$1.3940N/AN/AN/A5/14/2026Q1 2026DAREDare Bioscience-$0.33-$0.20+$0.13-$0.21$0.03 million$0.15 million5/7/2026Q1 2026ALGSAligos Therapeutics-$2.29-$2.21+$0.08-$2.21$0.25 million$2.83 million3/26/2026Q4 2025DAREDare Bioscience-$0.44-$0.02+$0.42-$0.02$0.75 million$1.02 million3/5/2026Q4 2025ALGSAligos Therapeutics-$2.09-$1.91+$0.18-$1.91$0.27 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AALGSAligos TherapeuticsN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/AALGSAligos TherapeuticsN/A2.562.56DAREDare BioscienceN/A1.031.03NCNANuCanaN/A5.485.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%ALGSAligos Therapeutics60.43%DAREDare Bioscience6.70%NCNANuCana44.00%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%ALGSAligos Therapeutics7.80%DAREDare Bioscience4.10%NCNANuCana31.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2059.31 million42.36 millionNot OptionableALGSAligos Therapeutics906.19 million5.71 millionNo DataDAREDare Bioscience3014.98 million14.37 millionNot OptionableNCNANuCana304.16 million2.86 millionNot OptionableNCNA, ADXS, DARE, and ALGS HeadlinesRecent News About These CompaniesNuCana Appoints Ian Webster as Chief Financial OfficerJune 1, 2026 | globenewswire.comNuCana Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14, 2026 | globenewswire.comNuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029March 22, 2026 | theglobeandmail.comNuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business UpdateMarch 19, 2026 | globenewswire.comNuCana plc: NuCana Appoints Theresa Bruce as Chief Operating OfficerJanuary 6, 2026 | finanznachrichten.deNuCana appoints Bruce as COOJanuary 6, 2026 | msn.comNuCana Appoints Theresa Bruce as Chief Operating OfficerJanuary 6, 2026 | globenewswire.comNuCana announces return of CEO Hugh S Griffith following health leaveDecember 17, 2025 | msn.comNuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 ...December 10, 2025 | bakersfield.comBNuCana presents latest clinical data at ESMO 2025 on NUC-7738December 10, 2025 | msn.comNuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant MelanomaDecember 10, 2025 | globenewswire.comNuCana Reports Q3 2025 Financial Results and Board ResignationNovember 13, 2025 | msn.comNuCana plc: NuCana Reports Third Quarter 2025 Financial Results and Provides Business UpdateNovember 13, 2025 | finanznachrichten.deNuCana Reports Third Quarter 2025 Financial Results and Provides Business UpdateNovember 13, 2025 | globenewswire.comNuCana stock rises after securing key patent in China for cancer drugNovember 5, 2025 | za.investing.comNuCana Shares Climb After Securing Key Chinese Patent for Cancer Drug NUC-7738November 5, 2025 | msn.comNuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in ChinaNovember 5, 2025 | globenewswire.comNuCana presents data at ESMO 2025 for NUC-7738, PD-1 inhibitorsOctober 19, 2025 | msn.comNuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ...October 18, 2025 | finance.yahoo.comNuCana announces publication of new data for NUC-3373October 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNCNA, ADXS, DARE, and ALGS Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.60 0.00 (0.00%) As of 06/4/2026Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Aligos Therapeutics NASDAQ:ALGS$4.91 -0.43 (-8.05%) Closing price 04:00 PM EasternExtended Trading$5.07 +0.16 (+3.34%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Dare Bioscience NASDAQ:DARE$1.88 -0.30 (-13.76%) Closing price 04:00 PM EasternExtended Trading$1.95 +0.07 (+3.72%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.NuCana NASDAQ:NCNA$1.95 -0.07 (-3.47%) Closing price 04:00 PM EasternExtended Trading$1.98 +0.03 (+1.54%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
